Yi Liu

7220818, May 22, 2007

Aug 16, 2004

10/919659

J. Fraser Stoddart - Los Angeles CA, US
Alexander Star - Pittsburgh PA, US
Yi Liu - San Diego CA, US
Ludek Ridvan - Prague, CZ

The Regents of the University of California - Oakland CA

C08G 75/00

528377, 528 86, 429212, 429213, 429209

Nanotubes are treated with poly{(5-alkoxy-m-phenylenevinylene)-co-[(2,5-dioctyloxy-p-phenylene)vinylene]} (PAmPV) polymers and derivatives thereof to provide noncovalent functionalization of the nanotubes which increases solubility and enhances other properties.

20070117964, May 24, 2007

Jan 16, 2007

11/653364

J. Stoddart - Los Angeles CA, US
Alexander Star - Pittsburgh PA, US
Yi Liu - San Diego CA, US
Ludek Ridvan - Praha, CZ

The Regents of the University of California - Oakland CA

C08G 75/32

528377000

Nanotubes are treated with poly{(5-alkoxy-m-phenylenevinylene)-co-[(2,5-dioctyloxy-p-phenylene)vinylene]} (PAmPV) polymers and derivatives thereof to provide noncovalent functionalization of the nanotubes which increases solubility and enhances other properties.

20110269779, Nov 3, 2011

Nov 17, 2009

13/127973

Troy Edward Wilson - San Marino CA, US
Christian Rommel - La Jolla CA, US
Yi Liu - San Diego CA, US
Pingda Ren - San Diego CA, US

INTELLIKINE, INC. - La Jolla CA

A61K 31/519
A61K 31/436
A61P 27/02
C12N 5/02

5142621, 435375, 514291, 5142641

The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating signal transduction by certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PB kinase in an ocular tissue. Also provided in the present invention are methods of using these compositions to modulate activities of one or more of these kinases, especially for therapeutic applications.

20140030759, Jan 30, 2014

Sep 26, 2013

14/038328

Linh Q. Le - Tustin CA, US
Yi Liu - Irvine CA, US
Lance E. Steward - Irvine CA, US

Allergan, Inc. - Irvine CA

C12P 21/00

435 681

The present specification discloses expression constructs comprising single-chain proteins comprising a di-chain loop region comprising an exogenous protease cleavage site and a protease that can cleave the exogenous protease cleavage site located within the di-chain loop, cell compositions comprising such expression construct, and intracellular methods of converting the single-chain protein into its di-chain form.

20220310530, Sep 29, 2022

Mar 22, 2022

17/655801

- Irvine CA, US
Hoang Mong Nguyen - Fountain Valley CA, US
Matthew Sean Read - Foothill Ranch CA, US
Howard E. Chen - Anaheim CA, US
Ki Wook Lee - Irvine CA, US
Yi Liu - San Diego CA, US

H01L 23/552
H01L 23/31
H01L 25/065
H01L 23/498
H01L 21/56
H01L 21/48
H01L 25/00

A packaged semiconductor module comprises a substrate having a ground plane, an electronic device mounted on a surface of the substrate, a bond pad disposed on the surface of the substrate and electrically connected to the ground plane, a mold compound covering the electronic device, a conductive post disposed on a side of the electronic device, the conductive post extending from the bond pad and at least partially through the mold compound, and a conductive layer disposed on the mold compound and electrically coupled to the conductive post and to the ground plane, the conductive post, the conductive layer, and the ground plane together forming the integrated electromagnetic interference shield, the conductive post extending from the bond pad to the conductive layer in a direction perpendicular to a plane defined by the surface of the substrate.

20180318355, Nov 8, 2018

Dec 7, 2017

15/834567

- Los Angeles CA, US
Yi Liu - Alhambra CA, US
Lei Wang - Monterey Patk CA, US

Alfred E. Mann Institute for Biomedical Eng. at the University of Southern California - Los Angeles CA

A61K 35/28
A61L 27/54
A61L 27/38
A61K 31/616
A61K 45/06
A61K 35/17

The present invention discloses methods, compositions and devices for improving tissue regeneration by suppressing the effects of several proinflammatory cytokines such as TNF-α and IFN-γ. Compositions and devices of this invention will generally include one or more anti-inflammatory agent(s) capable of reducing the level of TNF-α, IFN-γ, or both. Methods for improving tissue regeneration in accordance with this invention will generally have the step of applying a composition or device of the invention to a site in need of the composition or device. Also disclosed are methods for forming composition and devices of the invention and pharmaceutical compositions comprising one or more anti-inflammatory agent(s) effective of inhibiting or reducing the levels of TNF-α, IFN-γ, or both.

20160319265, Nov 3, 2016

May 16, 2016

15/155302

- Irvine CA, US
Linh Q. Le - Tustin CA, US
Yi Liu - Irvine CA, US
Lance E. Steward - Irvine CA, US

C12N 9/52
C12N 9/50
C12N 15/70
C12P 21/06
C07K 14/33

The present specification discloses expression constructs comprising single-chain proteins comprising a di-chain loop region comprising an exogenous protease cleavage site and a protease that can cleave the exogenous protease cleavage site located within the di-chain loop, cell compositions comprising such expression construct, and intracellular methods of converting the single-chain protein into its di-chain form.

20140154220, Jun 5, 2014

Apr 25, 2012

14/114070

Songtao Shi - Thousand Oaks CA, US
Yi Liu - Alhambra CA, US
Lei Wang - Monterey Park CA, US

University of Southern Califonia - Los Angels CA

A61K 35/28
A61K 31/616

424 937

The present invention discloses methods, compositions and devices for improving tissue regeneration by suppressing the effects of several proinflammatory cytokines such as TNF-α and IFN-γ. Compositions and devices of this invention will generally include one or more anti-inflammatory agent(s) capable of reducing the level of TNF-α, IFN-γ, or both. Methods for improving tissue regeneration in accordance with this invention will generally have the step of applying a composition or device of the invention to a site in need of the composition or device. Also disclosed are methods for forming composition and devices of the invention and pharmaceutical compositions comprising one or more anti-inflammatory agent(s) effective of inhibiting or reducing the levels of TNF-α, IFN-γ, or both.